Trial Transparency Challenges
The discussion highlights the complexities of selecting test groups in drug trials, particularly in the context of personalized medicine. Niki emphasizes the need for established protocols to match test and control groups, while Kyle raises concerns about hidden variables, especially genetic ones. The conversation underscores the current limitations in understanding the genome and the implications for transparency in trial results.In this clip
From this podcast
Data Skeptic
Personalized Medicine with Niki Athanasiadou
Related Questions